Michael P Weiner
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$6.4MFederal grants as PI11 awards
1Patents grantedLatest Dec 30, 2025
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
11 awards · $6.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 25, 2026 | NIH | SBIR Phase II DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs | $301K | ABBRATECH INC. |
| Jul 17, 2025 | NIH | SBIR Phase II DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs | $551K | ABBRATECH INC. |
| Dec 6, 2024 | NIH | SBIR Phase II A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D | $1 | ABBRATECH INC. |
| Sep 20, 2024 | NIH | SBIR Phase II DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs | $206K | ABBRATECH INC. |
| Aug 21, 2024 | NIH | SBIR Phase II Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. | $1.1M | ABBRATECH INC. |
| Jan 12, 2024 | NIH | SBIR Phase II Platform for the High Throughput Generation and Validation of Affinity Reagents | $1.1M | ABBRATECH INC. |
| Sep 19, 2023 | NIH | SBIR Phase II Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. | $1.1M | ABBRATECH INC. |
| Jun 22, 2023 | NIH | SBIR Phase I T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy | $295K | ABBRATECH INC. |
| Jan 26, 2023 | NIH | SBIR Phase II Platform for the High Throughput Generation and Validation of Affinity Reagents | $1.1M | ABBRATECH INC. |
| Jun 1, 2022 | NIH | SBIR Phase I Method for the isolation of antibodies with functional activity against cell surface targets | $253K | ABBRATECH INC. |
| Mar 23, 2022 | NIH | SBIR Phase I Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. I. survey of existing antibodies, and II. development of method improvements | $339K | ABBRATECH INC. |
2 patents as inventor
- US 12509508ABBRATECH INC.Dec 30, 2025
- US ABBRATECH INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#166
Awards as PI#106
Patents#155
Companies
- ABBRATECH INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.